Home | About IJMPO | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Indian Journal of Medical and Paediatric Oncology
Search Article 
  
Advanced search 
 

EDITORIAL
Year : 2010  |  Volume : 31  |  Issue : 1  |  Page : 1-3 Table of Contents     

Oral systemic therapy: Not all "win-win"


Department of Medical Oncology and Clinical Hematology, AMRI Hospitals, Gariahat Road, Orchid Nursing Home, C I T Road, Scheme VI M, Phoolbagan, Kolkata, India

Date of Web Publication27-Aug-2010

Correspondence Address:
G S Bhattacharyya
Department of Medical Oncology and Clinical Hematology, AMRI Hospitals, Gariahat Road, Orchid Nursing Home, C I T Road, Scheme VI M, Phoolbagan, Kolkata
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0971-5851.68844

Rights and Permissions

How to cite this article:
Bhattacharyya G S. Oral systemic therapy: Not all "win-win". Indian J Med Paediatr Oncol 2010;31:1-3

How to cite this URL:
Bhattacharyya G S. Oral systemic therapy: Not all "win-win". Indian J Med Paediatr Oncol [serial online] 2010 [cited 2020 Sep 18];31:1-3. Available from: http://www.ijmpo.org/text.asp?2010/31/1/1/68844

The approach to cancer treatment has changed in recent years, based on research that identifies new targets and develops agents to specifically target the targets. The discovery and clinical development of such molecules has led to a new class of agents, mostly for oral administration.

Oral therapeutic agents that target receptor tyrosine kinases (e.g., imatinib, dasatinib, sorafenib, sunitinib, lapatinib) or histone deacetylases (e.g., vorinostat) were introduced in this decade. Lenalidomide, an analogue of thalido­mide, was also recently introduced. Lenalidomide and vorinostat have immunomodulatory, anti-inflam­matory, and antiangiogenic proper­ties. While standard chemotherapy drugs are usually administered intravenously and continue to be the mainstay of systemic therapy, this new and growing list of orally administered agents is rapidly gaining prominence. In fact, some of these drugs, such as imatinib in chronic myeloid leukemia and thalidomide/lenalidomide in myeloma, have become the current standards of care for these diseases. Moreover, a few classical chemotherapy drugs, such as capecitabine, etoposide, and uracil/tegafur, are also in widespread use in the management of many important cancers. Is this new trend towards orally administered anticancer drugs all for the better?

Advantages of oral chemotherapy

Better patient convenience is the biggest ostensible advantage of orally administered drugs. The flexibility of tim­ing and drug exposure, location of administration, and non-invasiveness are among the other advantages. Oral administration provides more prolonged drug exposure compared with intermittent intravenous infusion, which may be important for drugs with schedule-dependent efficacy. The in vivo expo­sure to a drug is related to concentration and time. Thus, a drug with a short half-life can achieve a greater exposure time by either continuous infusion or by continuous oral dosing. This expo­sure time can have profound effects on toxicity (e.g., with antifolates) or efficacy (e.g., phosphorylation). [1] The use of oral therapy has the poten­tial to reduce the cost of healthcare resources for inpatient and ambula­tory patient care services. For example, there could be less use of supplies and ancillary support personnel like nurses and techni­cians. Finally, oral therapy may be associated with a better quality of life compared to parenteral administration.

Challenges associated with oral chemotherapy

Several potential problems arise uniquely because of the use of oral ­therapy. Oncologists need to be aware of these potential problems and take steps to avoid or minimize them in order to maintain the advantages and efficacy of oral agents. Oral therapeutic agents interact with other prescription and non-prescription drugs as well as with food, nutritional supplements, and herbal remedies. Some agents (e.g., sorafenib) should not be taken with food, especially high-fat food, because the latter reduces drug absorp­tion and bioavailability. In contrast, other agents (e.g., imatinib) should be taken with food to reduce gastrointestinal irritation. With other drugs like tamoxifen, there could be significant loss of efficacy due to interaction with other drugs like antidepressants. Dysphagia, odynophagia, nausea, and vomiting can all present as barriers to the use of the oral agents, causing missed doses or precluding treat­ment by the oral route. Drug absorp­tion may also be reduced in patients who vomit within a short time after taking a dose. Malabsorption, post-gastrectomy, and diarrhea can have major effects on drug absorption.

The toxicity profiles of many newer agents differ from those of traditional chemotherapy drugs. While this allows patients to avoid some, other equally frustrating adverse effects like rashes, skin hypo- and hyperpigmentation, hand-foot syndrome, hypertension, proteinuria, hypothyroidism, cardiac failure, and fluid retention have emerged in recent literature.

Non-adherence to the prescribed treatment is another potential problem with the use of oral agents at home or other non-traditional settings like as­sisted living facility, rehabilitation center, nursing home, or hospice. Non-adherence may be the result of con­fusion and misunderstanding about the treatment regimen or failure to remember doses. This problem can be confounded if the patients try to catch up on missed doses. This prob­lem is avoided with paren­teral therapy given in a clinic setting under the supervision of healthcare providers.

The counseling of patient or caregiver, which is given on oral therapy, must address the unique adverse effect profile associated with each agent. For example, life-threatening birth defects are associ­ated with lenalidomide and thalido­mide, and male and female patients receiving these drugs are required to comply with specific requirements designed to prevent fetal exposure to the drug.

Lastly, the prohibitive cost of some of these targeted oral agents is a pressing concern that precludes their use by the majority of our patients and their possible (and inappropriate) rationing by patients who use them.

Pharmacokinetics

The pharmacokinetic properties of the oral agents must also be consid­ered. The ideal oral agent lacks inter-pa­tient variability (i.e., among different individuals) in absorption and area under the plasma concentration-time curve (i.e., exposure). A lack of in­tra-patient variability (i.e., over time in the same individual) in pharmacokinetics with repeated dosing (i.e., no drug accumulation) or lack of induced metabolism is also desir­able. Another important ideal is the dosing algorithm. A simple basis for dosing, i.e., a flat dose that is taken by all patients every day instead of an individualized dose based on weight or body surface area, would minimize confusion and promote adherence. Ideally, a dose strength that cor­responds to the flat dose would be very desirable so that patients would not need to take multiple tablets or capsules at each dose and thus mini­mize errors.

The pharmacokinetic properties of currently avail­able oral agents depend on the specific agent. For ex­ample, the absorption of etoposide is saturable, resulting in lower bioavailability at large dosages compared with smaller ones. A high-fat meal decreases the absorption of some agents (e.g., sorafenib) and increases the absorption of vorinostat and other agents. In addition, oral drugs are subject to degradation in the gastrointestinal tract. The solubility of dasatinib is pH depen­dent, and acid suppression from pro­ton pump inhibitors, H2-receptor antagonists, or antacids can reduce the exposure to dasatinib. Certain oral chemotherapeutic agents (e.g., etoposide, cyclophos­phamide) are subject to first-pass metabolism by intestinal and hepatic cytochrome P-450 (CYP) enzymes; particularly the 3A4 isoenzyme. The bioavailability of substrates for this isoenzyme may be reduced when the drug is administered orally compared with the parenteral route. Bioavail­ability also may be affected by drugs that induce or inhibit CYP 3A4.

The membrane-bound p-glycoprotein transporters, lo­cated near CYP 3A4 in the intestinal epithelium, can affect the absorption and bioavailability of chemothera­peutic agents. The gene that en­codes p-glycoprotein exhibits genetic polymorphism (i.e., variability), [2] and can greatly affect intracellular ex­posure. Other drugs can induce or inhibit p-glycoprotein, affecting the bioavailability of oral agents. Drug activation is also an im­portant factor. [3] Capecitabine, an oral pro-drug of 5-fluorouracil (5-FU), undergoes activation through a multiple-step process. The enzyme involved in the final activation step, thymidine phosphorylase, exhibits polymorphism that can affect pharmacokinetics and patient outcomes. [4] An understanding of the pharma­cokinetic variables that can affect the absorption and disposition of oral chemotherapy may allow modifica­tion of drug therapy so that patient outcomes are optimized.

Comparative studies

The pharmacokinetics of oral che­motherapeutic agents are well char­acterized by the time the products are introduced, but studies comparing the clinical efficacy and safety of oral and parenteral forms of the same drug or a pro-drug are less common. Oral 5-FU pro-drugs and intravenous 5-FU are an exception in that they have been compared in several clinical studies. In two phase III randomized studies with a total of 1207 patients with previously untreated metastatic colorectal cancer, the response rate was 26% with oral capecitabine and 17%. With IV bolus of 5FU plus leucovorin (the Mayo Clinic regimen), a difference that is statistically significant. [5] The time to disease progression and overall survival were similar in the two treat­ment groups, however. A comparison of safety profiles favored capecitabine over 5-FU plus leucovorin. [6]

The efficacy and safety of oral capecitabine and intravenous bolus of 5FU plus leucovorin (the Mayo Clinic regi­men) were compared over a 24-week period in the adjuvant setting in an­other randomized study of 1987 pa­tients with resected stage III (Dukes' C) colon cancer. The relapse-free survival was significantly greater in the capecitabine-treated group than in the group receiving 5-FU plus leucovorin. Capecitabine was at least as effective as 5-FU plus leucovorin in increasing disease-free survival and overall survival. Significantly fewer adverse effects were associated with capecitabine than 5-FU plus leucovorin. In the National Surgical Adjuvant Breast and Bowel Project (NSABP), oral uracil plus the 5-FU pro-drug tegafur (ftorafur), a fluoro-pyrimidine combination referred to as UFT, plus leucovorin was compared with intravenous 5-FU plus leucovorin (the Roswell Park regimen) in 1608 patients with stage II or III carcinoma of the co­lon. There was no significant dif­ference between the two treatment groups in overall survival or disease-free survival. The toxicities were similar in the two treatment groups. These studies demonstrate that use of the oral route of administra­tion for 5-FU pro-drugs instead of the intravenous route does not compromise the efficacy or safety of chemotherapy. Additional research is needed to compare outcomes when other oral chemotherapies are used instead of parenteral chemotherapy. [7]

Patient preference

Patient preference for the route of chemotherapy administration was evaluated by interviews conducted in 103 patients with incurable cancer, who anticipated receiving palliative che­motherapy. The majority of pa­tients (90%) preferred the oral route, primarily because of greater convenience (57%), problems with intravenous access, fear of needles (55%) or a better environment for administration of medication (i.e., the home setting). Ten patients preferred the intravenous route, and one patient had no preference for route of administra­tion. Although most patients had a preference for one of the routes of admin­istration, a lower response rate or shorter duration of response was not an acceptable trade-off for 70 and 74% patients, respec­tively. Thirty-nine percent of patients wanted the decision about route of administration to be made primarily by the physician. [8]

In a randomized crossover study, 37 previously untreated patients with advanced colorectal cancer were treated with oral UFT plus leucovo­rin for 28 days every 5 weeks or intravenous 5-FU plus leucovorin for 5 days ev­ery 4 weeks for the first treatment cycle and then they were crossed over to the other treatment for the sec­ond treatment cycle. Twenty-seven (84%) of 32 patients completing a questionnaire preferred oral UFT over intravenous 5-FU. [9] The ability to take the medication at home, less stomatitis and diarrhea, and preference for an oral dosage form were cited by patients as the most important reasons for these preferences. [8]

Quality of life

Studies comparing the qual­ity of life associated with oral and intravenous chemotherapy using validat­ed instruments are limited. The Functional Assessment of Cancer Therapy-Colorectal (FACT-C) scale, a validated tool for measuring qual­ity of life, and a convenience-of-care analysis were used in the NSABP trial in which oral UFT plus leucovorin was compared to intravenous 5-FU plus leucovorin in patients with colon carcinoma in the adjuvant setting. There were no significant differences between the two treatment groups in FACT-C scores or overall quality of life. However, oral UFT plus leucovorin was associated with a signifi­cantly higher convenience-of-care score than intravenous 5-FU plus leucovorin. [10]


  Conclusion Top


Patients receiving chemotherapy prefer the oral route of adminis­tration over the parenteral route because of greater convenience and flexibility in the location and scheduling of medication adminis­tration. Awareness in clinicians of the potential challenges of oral drugs can help optimize pa­tient outcomes. Additional studies comparing more oral and parenteral forms of chemotherapeutic agents are warranted.

 
  References Top

1.Toffoli G, Corona G, Basso B, Boiocchi M. Phar­macokinetic optimization of treatment with oral etoposide. Clin Pharmacokinet 2004;43:441-66.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]  
2.Davis M. Gender differences in p-glycoprotein: Drug toxicity and response. J Clin Oncol 2005;23:6439-40.  Back to cited text no. 2  [PUBMED]  [FULLTEXT]  
3.Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be mini­mized? Crit Rev Oncol Hematol 2005;55:117-42.  Back to cited text no. 3  [PUBMED]  [FULLTEXT]  
4.Largillier R, Etienne-Grimaldi MC, Formento JL, Ciccolini J, Nebbia JF, Ginot A, et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin Cancer Res 2006;12:5496-502.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]  
5.Van Cutsem E, Hoff PM, Harper P, Bukowski RM, Cunningham D, Dufour P, et al. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: Integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:1190-7.  Back to cited text no. 5      
6.Twelves C, Wong A, Nowacki MP, Abt M, Burris H 3 rd , Carrato A, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005;352:2696-704.  Back to cited text no. 6      
7.Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carci­noma of the colon: Results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006;24:2059-64.  Back to cited text no. 7  [PUBMED]  [FULLTEXT]  
8.Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997;15:110-5.   Back to cited text no. 8  [PUBMED]  [FULLTEXT]  
9.Borner M, Schsffski P, de Wit R, Caponigro F, Comella G, Sulkes A, Peters G, Grynwald V, Wanders J, de Boer R, Mrtin C, Fumoleau P (2000) A randomized crossover trial comparing oral UFT Uracil/tegafur)+leucovorin (LV) and intravenous fluorouracil (FU)+LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol 19:741.  Back to cited text no. 9      
10.Ward WL, Hahn EA, Mo F, Hernandez L, Tulsky DS, Cella D. Reliability and validity of the functional assessment of cancer therapy-colorectal (FACT-C) quality of life instrument. Qual Life Res 1999;8:181-95.  Back to cited text no. 10  [PUBMED]  [FULLTEXT]  



This article has been cited by
1 Bleomycin sulphate loaded nanostructured lipid particles augment oral bioavailability, cytotoxicity and apoptosis in cervical cancer cells
Jyoti Saini,Vikas Bansal,Ankush Chandra,Jitender Madan,Upendra Kumar Jain,Ramesh Chandra,Sarvesh Malviya Jain
Colloids and Surfaces B: Biointerfaces. 2014;
[Pubmed] | [DOI]



 

Top
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
   Conclusion
   References

 Article Access Statistics
    Viewed2234    
    Printed112    
    Emailed1    
    PDF Downloaded294    
    Comments [Add]    
    Cited by others 1    

Recommend this journal